Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Imidafenacin is a potent, selective muscarinic M3 receptor antagonist developed primarily for the management of overactive bladder (OAB). Its chemical identity is defined by the molecular formula C21H25N3O and carries the CAS Registry Number 187649-70-1. Structurally, it belongs to the class of antimuscarinic agents designed to target specific receptor subtypes involved in bladder smooth muscle contraction. By selectively blocking M3 receptors located on the detrusor muscle of the urinary bladder, Imidafenacin effectively inhibits involuntary contractions, thereby increasing bladder capacity and reducing the frequency of urgency episodes.
The primary clinical utility of Imidafenacin lies in alleviating the hallmark symptoms of OAB, including urinary urgency, frequent voiding, and urge urinary incontinence. Unlike older non-selective anticholinergics that block multiple muscarinic receptor subtypes (M1, M2, M3, etc.), Imidafenacin exhibits high selectivity for the M3 subtype. This pharmacological profile aims to maximize therapeutic efficacy while minimizing common side effects associated with broader receptor blockade, such as dry mouth, constipation, blurred vision, and cognitive impairment. Clinical studies have demonstrated its ability to significantly improve quality of life for patients suffering from OAB, offering a favorable safety profile compared to traditional alternatives like oxybutynin or tolterodine.
Approved in Japan and other regions, Imidafenacin is typically administered orally in tablet form, often dosed once daily due to its sustained release properties and long half-life. While generally well-tolerated, patients may still experience mild anticholinergic effects, though the incidence is notably lower than with non-selective agents. It is contraindicated in individuals with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug. As research into urological disorders advances, Imidafenacin remains a cornerstone therapy for managing bladder dysfunction, balancing symptom control with patient comfort. Its development represents a significant step toward targeted pharmacotherapy, ensuring effective treatment with reduced systemic burden for those living with overactive bladder syndrome.